Vincenzo Tarzia

Dr. Vincenzo Tarzia


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2014 in JAMA
Verified
Journal Article
Open access
PDF file
MIMassimo Imazio
Massimo Imazio
ABAntonio Brucato
Antonio Brucato
PFPaolo Ferrazzi
Paolo Ferrazzi
APAlberto Pullara
Alberto Pullara
YAYehuda Adler
Yehuda Adler
FGFiorenzo Gaita
Fiorenzo Gaita
Postpericardiotomy syndrome, postoperative atrial fibrillation (AF), and postoperative pericardial/pleural effusions are common complications after cardiac surgery, affecting more than one-third of patients, an incidence largely unchanged despite advances in surgical techniques, anesthetic procedures, and perioperative care.1-6

19 July 2013 in Xenotransplantation
Verified
Journal Article
Open access
PDF file
FNFilippo Naso
Filippo Naso
AGAlessandro Gandaglia
Alessandro Gandaglia
TBTomaso Bottio
Tomaso Bottio
VTVincenzo Tarzia
Vincenzo Tarzia
MNMark B. Nottle
Mark B. Nottle
Giacomo GerosaGiacomo Gerosa
Giacomo Gerosa
Background: Glutaraldehyde fixation does not guarantee complete tissue biocompatibility in current clinical bioprosthetic heart valves (BHVs). Particularly, circulating anti‐αGal human antibodies increase significantly from just 10 days after a BHV implantation. The inactivation of such epitope should be mandatory to meet the requirements for a perspectively safe clinical application; nevertheless, its quantitative assessment in commercially available BHVs has never been carried out.Methods: In this investigation, seven different models of BHVs were tested. The number of epitopes was determined with reference to a standard αGal source by an ELISA test. The presence of xenoantigen was subsequently confirmed by immunofluorescence analysis. Porcine tissue, knockout for the αGal epitopes, was used as negative control.Results: Epic™ valve was the only model among those tested, in which the αGal antigen appeared to be completely shielded. Composite Trifecta™ valve exhibited conflicting results: cusps of bovine pericardial tissue were devoid of reactive αGal epitopes, while the stent cover strip of porcine pericardium still maintained 30% of active antigens originally present in native tissue. All other tested BHVs express an αGal amount not significantly different from that exhibited by porcine Mosaic® valve (5.2 ± 0.6 × 1010 each 10 mg of tissue).Conclusions: For the first time, the quantitative evaluation of the αGal epitope in heart valve bioprostheses, already in clinical practice for about 40 yrs, was finally determined. Such quantification might provide indications of biocompatibility relevant for the selection of bioprosthetic devices and an increase in the confidence of the patient. It might become a major quality control tool in the production and redirection of future investigation in the quest for αGal‐free long‐lasting substitutes.

1 November 2014 in ASAIO Journal
Verified
Journal Article
Closed access
GTGianluca Torregrossa
Gianluca Torregrossa
MMMichiel Morshuis
Michiel Morshuis
RVRobin Varghese
Robin Varghese
LHLeila Hosseinian
Leila Hosseinian
VVVladimiro Vida
Vladimiro Vida
GGGino Gerosa
Gino Gerosa
Mechanical circulatory support devices have been increasingly used for long-term support. We reviewed outcomes in all patients supported with a SynCardia total artificial heart (TAH) for more than 1 year to assess its safety in long-term support. As of December 2011, all 47 patients who received the TAH from 10 centers worldwide were included in this retrospective study. Clinical data were collected on survival, infections, thromboembolic and hemorrhagic events, device failures, and antithrombotic therapy. The mean age of patients was 50 ± 1.57 years, the median support time was 554 days (range 365-1373 days). The primary diagnosis was dilated cardiomiopathy in 23 patients, ischemic in 15, and "other" in 9. After a minimum of 1 year of support, 34 patients (72%) were successfully transplanted, 12 patients (24%) died while on device support, and 1 patient (2%) is still supported. Five patients (10%) had a device failure reported. Major complications were as follows: systemic infections in 25 patients (53%), driveline infections in 13 patients (27%), thromboembolic events in 9 patients (19%), and hemorrhagic events in 7 patients (14%). SynCardia TAH has proven to be a reliable and effective device in replacing the entire heart. In patients who reached a minimum of 1 year of support, device failure rate is acceptable and only in two cases was the leading cause of death. Infections and hemorrhagic events were the major causes of death. Patients who remain supported beyond 1 year are still likely to survive to transplantation.

1 August 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
VTVincenzo Tarzia
Vincenzo Tarzia
GBGiacomo Bortolussi
Giacomo Bortolussi
RBRoberto Bianco
Roberto Bianco
EBEdward Buratto
Edward Buratto
JBJonida Bejko
Jonida Bejko
GGGino Gerosa
Gino Gerosa

1 August 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
Michele Di MauroMichele Di Mauro
Michele Di Mauro
GDGuglielmo Mario Actis Dato
Guglielmo Mario Actis Dato
FBFabio Barili
Fabio Barili
SGSandro Gelsomino
Sandro Gelsomino
PSPasquale Santè
Pasquale Santè
GNGiannantonio Nappi
Giannantonio Nappi

1 May 2006 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
Giacomo GerosaGiacomo Gerosa
Giacomo Gerosa
VTVincenzo Tarzia
Vincenzo Tarzia
GRGiulio Rizzoli
Giulio Rizzoli
TBTomaso Bottio
Tomaso Bottio